Neoadjuvant chemotherapy for gastric cancer

Surgery remains the cornerstone of curative treatment for gastric cancer (GC). However, randomised controlled trials (RCTs) have established a multi-disciplinary approach in the treatment of resectable GC. Interestingly, trials conducted in different parts of the world have given rise to varying standards of care. Generally, except patients with T1N0 or intramucosal tumour, all patients with resectable GC should be considered for a multi-modality treatment plan, preferably decided by a multi-disciplinary team.